| Name | Title | Contact Details |
|---|---|---|
Prakash Uddagatti |
Director of IT | Profile |
GCX Corporation is a Petaluma, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize treatment of chronic disease.
Regal Medical Group is dedicated to delivering high quality of care with an emphasis of continuously improving service quality. Some of the benefits of being a Regal Provider are the tools and support we give the providers to effectively care for the
Mazor Robotics Renaissance Guidance System is transforming spine surgery from freehand operations to highly-accurate, state-of-the-art procedures that may reduce fluoroscopy. It is the only mechanical guidance system for spine surgery with FDA clearance and CE marking. Renaissance has been used in thousands of spine procedures worldwide ranging from minimally-invasive surgery to scoliosis and other complex spinal deformity cases.
At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.